Added to YB: 2026-05-01
Pitch date: 2026-04-30
PSNL [bullish]
Personalis, Inc.
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.
Market Cap
$527.6M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-4.73
P/E
-5.53
EV/Sales
4.76
Sector
Life Sciences Tools and Services
Category
growth
Show full summary:
Pitch Time: $PSNL
PSNL: Cancer detection test w/ higher sensitivity than $NTRA. Secured reimbursement for breast & lung (IO pending). Margins to expand from 11% to 60%+ as reimbursement pricing kicks in. Clinical volumes to 3x in 2026 via $TEM partnership (owns 20%). 35% net margin potential at scale. Cash burn to decline as margins improve.
Read full article (2 min)